ROKIT America, Inc. (RKAM)
ROKIT America will go public soon, but the exact IPO date is still unknown.
Stock Price: Pending
IPO price not available yet

Company Description

ROKIT America is committed to extending human healthspan and enhancing quality of life in an aging society through its proprietary Reverse Aging Product which is intended to support cellular health and aging-related biological processes at the molecular level, and its artificial intelligence hyper-personalized Organ Regeneration Platform, a proprietary technology developed by our parent company, ROKIT Healthcare, which is intended to provide regenerative medicine solutions in the Americas.

Since its founding in 2019, the Company has focused on the research and development of dietary supplements centered around β-Nicotinamide Mononucleotide (“NMN”).

We have launched a range of NMN-based products into global markets, including the United States. Our flagship product line, ROKIT AMERICA NMN, combines NMN with pterostilbene, a naturally occurring antioxidant.

ROKIT America, Inc.
CountryUnited States
Founded2019
IndustryPackaged Foods
SectorConsumer Staples
CEOSeok Hwan You

Contact Details

Address:
3435 Wilshire Blvd, Suite 2925
Los Angeles, CA 90010
United States
Phone(678) 861-0046
Websiterokitamerica.co.kr

Stock Details

Ticker SymbolRKAM
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code2087716
Employer ID38-4124442
SIC Code2834

Key Executives

NamePosition
Seok Hwan YouChief Executive Officer and Chairman of the Board of Directors
Ha Young KimChief Financial Officer and Director
Seong Mo JeeChief Strategy Officer
Min Gu LeeChief Medical Officer
Won Kyung ChoiChief Technology Officer
Woo Young KimChief Operation Officer
Min Kyoung ChoiChief Legal Officer

Latest SEC Filings

DateTypeTitle
Apr 15, 2026S-1General form for registration of securities under the Securities Act of 1933
Apr 2, 2026DRS/A[Amend] [Cover] Draft Registration Statement
Mar 11, 2026DRS/A[Amend] [Cover] Draft Registration Statement
Jan 16, 2026DRS/A[Amend] [Cover] Draft Registration Statement
Oct 2, 2025DRS[Cover] Draft Registration Statement